Skip to content

GenSight Biologics reports long-term positive safety and visual acuity results at Week 96 in Phase I/II Study of GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON)

Sustained clinically significant improvement of visual acuity in LHON patients with less than 2 years of visual loss
Confirmation of the long-term safety profile of GS010

Paris, France, June 14, 2017 – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today reported additional promising clinical trial results with GS010 after 96 weeks of follow-up in its Phase I/II study. These results confirm the long-term positive sustained visual acuity gain after 2 years with a single intravitreal injection of GS010 in patients with Leber’s Hereditary Optic Neuropathy (LHON), especially in those with less than 2 years of disease onset.

Please find the full PDF press release attached.gensightJune14


GenSight Biologics
Thomas Gidoin
Chief Financial Officer
+33 (0)1 76 21 72 20
nvestor Relations
Florent Alba
+33 (0)1 44 71 98 55
Rooney Partners
Media Relations
Marion Janic

Source: Gensight